News Gilead rescinds orphan status request for COVID-19 drug Gilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over its pricing should it get to market.
News Shire plans filing for HAE drug after phase 3 success Lanadelumab could revolutionise treatment of swelling disease.
News EUSA Pharma approval fills gap in neuroblastoma market Company can move in after United Therapeutics withdrew its product Unituxin
News EU regulators back two more orphan drugs, question of pricin... Two orphan medicines are heading towards the European market, after regulators recommended rare disease drugs from Biogen and BioMarin.
News Novartis and Allergan to combine drugs in NASH Swiss pharma also aims for new CAR-T therapy indication.
News Neumora laid low by depression trial failure The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.